



Appendix 32: EX1 Form (Initial Examination Report)

INITIAL EXAMINATION REPORT (MEDICAL – CONFIDENTIAL)

 Petroleum Development Oman MEDICAL DEPARTMENT PLEASE COMPLETE YOUR PERSONAL DETAILS IN BLOCK CAPITALS		Surname <u>AHMED</u> Forenames <u>EJAZ</u> Address _____ Home telephone number <u>95293385</u>	
Place of examination <u>ADAM-ADAM</u> Date <u>29/06/2025</u>		If a dependent enter employee's name here: Surname: _____ Forenames: <u>Ejaz Ahmed</u>	
Birth date: <u>01/01/1995</u>	Nationality: <u>QATAR</u>	Country of birth: <u>QATAR</u>	Religion: <u>Muslim</u>
☒ Male ☐ Female	☒ Married ☐ Single ☐ Separated /Divorced	Relationship to employee ☒ Wife ☐ Son ☒ Daughter	Number of children: <u>4</u>
Reason for examination: Pre-Employment ☐ Job: <u>Driver</u>		Pre-Overseas ☐ Area: <u>MUSMUL PDO</u>	
Name and address of family doctor _____		List your last 3 jobs (1) _____ (2) _____	
Are you a Registered Disabled Person? (UK only) ☐		Do you belong to any Medical Insurance Scheme? ☐	
DO YOU HAVE OR HAVE YOU HAD:- (Tick "Yes" or "No" column or put a (?) if uncertain exclude minor ailments.)			
Y N		Y N	
1. Sinus trouble	☒	21. Cancer	☒
2. Neck swelling/glands	☒	22. Heart Disease	☒
3. Difficulty in vision	☒	23. Rheumatic fever	☒
4. Any ear discharge	☒	24. Abnormal heartbeat	☒
5. Asthma/bronchitis	☒	25. High blood pressure	☒
6. Hayfever/other significant allergy	☒	26. Stroke	☒
7. Any skin trouble	☒	27. Serious chest pain	☒
8. Tuberculosis	☒	28. Any blood disease	☒
9. Shortness of breath	☒	29. Kidney disease	☒
10. Coughed/vomited blood	☒	30. Blood in urine	☒
11. Severe abdominal pain	☒	31. Diabetes	☒
12. Stomach ulcer	☒	32. Headaches/migraine	☒
13. Recurrent indigestion	☒	33. Dizziness/fainting	☒
14. Jaundice or hepatitis	☒	34. Epilepsy	☒
15. Gall Bladder disease	☒	35. Joints/spinal trouble	☒
16. Marked change in bowel habits	☒	36. Surgical operation	☒
17. Blood in stools (motions)	☒	37. Serious accident/fracture	☒
18. Marked change in weight	☒	38. Tropical disease	☒
19. Varicose veins	☒	39. Fear of heights	☒
20. Lump in breast/axilla	☒		
How much tobacco each day? <u>X</u>		Average daily alcohol consumption <u>X</u>	
Have you ever taken illicit drugs? <u>(X)</u> PDO test all new/potential employees for illicit/recreational drugs			
FAMILY HISTORY: Diabetes <u>(X)</u> Tuberculosis <u>(X)</u> Epilepsy <u>(X)</u> Asthma <u>(X)</u> Eczema <u>(X)</u> Heart disease <u>(X)</u> High blood pressure <u>(X)</u> Stroke <u>(X)</u> Blood Disease <u>(X)</u> Cancer <u>(X)</u>			
PLEASE READ THE FOLLOWING STATEMENT AND IF YOU AGREE KINDLY SIGN IT:- I declared these statements to be true to the best of my knowledge and belief and I agree that the result of this medical examination in general terms may be revealed to the Company if required, and the details sent to my own doctor if this is considered necessary by the examining medical officer. I am also aware that PDO reserve the right to dismiss me if it was found that I have purposely withheld important medical information.			
Date: <u>29.06.2025</u>		Signature of Applicant: _____	
Page 79		Specification <u>15/11/21</u>	
The controlled version of this CME Document resides online in L:\Link CME Documents\1426 016 CME Doc.			





Revision: 5.0
Effective: January 2022

FOR	COMPLETION	BY	EXAMINING	DOCTOR	OR	NURSE			
Further details of medical history and recreational activities									
Hypertension on R R last 5 yrs.									
N = Normal A = Abnormal (please describe)			PHYSICAL EXAMINATION						
N	A								
✓		1. Eyes & Pupils							
✓		2. E.N.T.							
✓		3. Teeth & Mouth							
✓		4. Lungs & Chest							
✓		5. Cardiovascular System							
✓		6. Abdo. Viscera							
✓		7. Hernial Orifices							
✓		8. Anus & Rectum							
✓		9. Genito-urinary							
✓		10. Extremities							
✓		11. Musculo-skeletal							
✓		12. Skin & Varicose Vns.							
✓		13. C.N.S.							
HEIGHT cm	WEIGHT kg	BMI	B.P.	PULSE	HEARING L R	VISION DISTANT R L Uncorrected Corrected	NEAR R L Uncorrected Corrected	Colour Vision	Blood Group
167	113.8	40.80	162/96 102	96 /mins.		6/6 6/6 6/6 6/6	6/6 6/6 6/6 6/6	38	
N	A	LABORATORY AND OTHER SPECIAL INVESTIGATIONS				N	A		
		1. Urinalysis						7. Audiogram	
		2. Hb, Bloodcount, ESR						8. Lung Function	
		3. LFT, RFT, RBS						9. Chest X-Ray	
		4. Drug Screen						10. ECG	
		5. Lipids (40 years +)						11. CVS risk for 40 yrs. & above	
		6. Sickie Cell test						12. HIV, Hepatitis screening	
OTHER FINDINGS (Physique, scars, disabilities, mental stability including behaviour, etc.)									
Hypertension, morbid obesity. Needs life style modification									
ASSESSMENT:									
☒ FIT ALL AREAS ☐ FIT WITH RESTRICTION ☐ TEMPORARY UNFIT ☐ UNFIT									
FIT									
30/6/2025 Date: Dr. Shiva Kumar Name (Block Capitals): Dr. / Nurse									
REVIEW/CONSULTATION									
30/6/2025 Date: Dr. Shiva Kumar Name (Block Capitals): Dr. / Nurse DR. SHIVA KUMAR SREKAIAH General Physician Mohan Medical Centre and specialty hospitals, Al Warf									
تمريض تسجيل C.R. No: 9668137 Software of Oman RECEPTION									



DEPARTMENT OF LABORATORY MEDICINE

File No: 50102041
Name: EJAZ AHMED

Address:

Gender: M Age: 53 Y Nationality: PAKISTANI
GSM No.: 95293385 ID Card No.: 69827461
Ref. By: DR ERFAN GHODJANI

Report No: 0157065
Sample Date: 28/06/2025 Time: 8:38
Received By:
Received Date: Time:
Report Date: 28/06/2025 Time: 10:17
Bill No: 0379123 Bill Date: 28/06/2025
Report Status: Final

INVESTIGATION	RESULT	REFERENCE RANGE
PDO Package – 2 (Above 50 yrs)		
COMPLETE BLOOD COUNT		
TOTAL WBC COUNT	10.43 x 10 ³ / μ L	4.00-11.00 x 10 ³ / μ L
DIFFERENTIAL COUNT		
NEUTROPHIL (%)	56.96 %	40-75%
LYMPHOCYTE (%)	31.46 %	20-45%
MONOCYTE (%)	5.78 %	2-8%
EOSINOPHIL (%)	4.64 %	1-6%
BASOPHIL (%)	1.16 %	0-1%
HAEMOGLOBIN	14.68 gm/dl	Male : 13 -18 gm/dl Female:11-15 gm /dl childrens upto 1year-11.0 - 13.0 gm /dl upto12years-11.5 - 14.5 gm /dl cord blood:13 -19.5 gm /dl
RBC COUNT	5.40 million/cu	Male :4.5-6.5 million/cu Female:3.9-5.5 million/cu
PLATELET COUNT	279.30 x 10 ³ / μ L	150 - 400 x 10 ³ / μ L
HEMATOCRIT	45.45 %	Male :42 - 52% Female:37- 47%
MCV	84.26 fl	76 - 96 fl
MCH	27.21 pg	27 - 33 pg
MCHC	32.30 gm/dl	32 - 36 gm/dl
SICKLE CELL	NEGATIVE	
Method : Solubility test (If Positive , Hb Electrophoresis / HPLC to be done to confirm Sickle cell anaemia / Trait).		
LIVER FUNCTION TEST		
TOTAL BILIRUBIN	8.00 μ mol/L	Adults:- up to 21 μ mol/L, Children >1 month - up to 17 μ mol/L, Neonates :- 1.7 - 180 μ mol/L

Verified By:

Approved By:

10593

Lab Technologist

MOH License No:
Electronically signed at: 0/28/2025 10:18:00

DR ROSE MARY

Specialist Pathologist

MOH License No: 18178
Electronically signed at: 28/06/2025 12:57:00

Printed at: 30/06/2025 11:51:29 AM

Page : 1 of 3



NMC Healthcare LLC
CR No: 165813/
Plot No: 294, Block: 33B
Building No: 012, J.B. Road, Jeddah
Saudia Arabia
T: +966 11 416 5200
F: +966 11 416 5209
www.nmc-hc.com

DEPARTMENT OF LABORATORY MEDICINE

File No: 50102041
Name: EJAZ AHMED

Report No: 0157065
Sample Date: 28/06/2025 Time: 8:38
Received By:
Received Date: Time:
Report Date: 28/06/2025 Time: 10:17
Bill No: 0379123 Bill Date: 28/06/2025
Report Status: Final

Address:
Gender: M Age: 53 Y Nationality: PAKISTANI
GSM No.: 95293385 ID Card No.: 69827461
Ref. By: DR ERFAN GHOOJANI

INVESTIGATION	RESULT	REFERENCE RANGE
DIRECT BILIRUBIN	3.50 μ mol/L	Adults :- 0 - 5.0 μ mol/L, Neonates:- 0-10 μ mol/L
TOTAL PROTIEN	83.10 g/L	Adults : 66 - 87 g/L
ALBUMIN	40.70 g/L	39.7 - 49.4 g/L
Globulin	42.4 g/L	23-35g/L
SGOT (AST)	15.90 U/L	MALE : up to 40 U/L, FEMALE : up to 32 U/L
SGPT (ALT)	9.60 U/L	MALE : up to 41 U/L, FEMALE : up to 33 U/L
ALKPO4 (ALP)	107.00 U/L	Adults: MALES: 40 - 129 U/L, FEMALES: 35 - 104 U/L
Gamma GT (GGT)	21.00 U/L	MALE- 8 - 61 U/L, FEMALE- 5 - 36 U/L
RENAL FUNCTION TEST		
URIC ACID	424.00 μ mol/L	MALE: 202.3 - 416.5 μ mol/L, FEMALE: 142.8 - 339.2 μ mol/L
CREATININE	82.00 μ mol/L	Adults: MALE: 62 - 106 μ mol/L FEMALE: 44 - 80 μ mol/L
UREA	5.70 mmol/L	2.70 - 8.07 mmol/L
LIPID PROFILE		
TOTAL CHOLESTEROL	3.47 mmol/L	< 5.18 mmol/L
HDL	1.10 mmol/L	>1.5 mmol/L
TRIGLYCERIDES	0.70 mmol/L	Desirable : <2.083 mmol/L Boderline high : 2.83 - 5.67 mmol/L Hypertriglyceridemia >5.65 mmol/L
LDL	1.98 mmol/L	< 2.6 mmol/L
VLDL	0.32 mmol/L	0.128-0.645mmol/L

Verified By:

Approved By:

10593

Lab Technologist

MCH License No:
Electronically signed at: 6/28/2025 10:18:00

DR ROSE MARY

Specialist Pathologist

MCH License No: 18178
Electronically signed at: 29/06/2025 12:59:00

Printed at: 30/06/2025 11:51:29 AM

Page: 2 of 3



NMC Healthcare LLC
CR No: 1000137
PO Box 291, Doha - 315
Building No B17, Al Khor Road,
Doha, Qatar
T: +974 4400 9222
F: +974 4400 9288
www.nmchealthcare.com

DEPARTMENT OF LABORATORY MEDICINE

File No: 50102041
Name: EJAZ AHMED

Address:
Gender: M Age: 53 Y Nationality: PAKISTANI
GSM No.: 95293385 ID Card No.: 69827461
Ref. By: DR ERFAN GHODJANI

Report No: 0157065
Sample Date: 28/06/2025 Time: 8:38
Received By:
Received Date: Time:
Report Date: 28/06/2025 Time: 10:17
Bill No: 0379123 Bill Date: 28/06/2025
Report Status: Final

INVESTIGATION	RESULT	REFERENCE RANGE
FASTING BLOOD SUGAR	6.27 mmol/L	4.11 - 6.05 mmol/L
URINE ROUTINE		
URINE BIOCHEMISTRY		
URINE GLUCOSE	NEGATIVE	NEGATIVE
URINE PROTEIN	NEGATIVE	NEGATIVE
URINE KETONE	NEGATIVE	NEGATIVE
URINE BILIRUBIN	NEGATIVE	NEGATIVE
NITRITE	NEGATIVE	NEGATIVE
URINE PH	6.0	4.6-8.0
SPECIFIC GRAVITY	1.015	1.010-1.030
BLOOD	NEGATIVE	NEGATIVE
UROBILINOGEN	NORMAL	NORMAL
URINE MACROSCOPY		
COLOUR	PALE YELLOW	
APPEARANCE	CLEAR	
URINE MICROSCOPY		
RBC	NIL /hpf	0-3
PUSCELLS	2-4 /hpf	0-5
EPITHELIAL CELLS	1-3 /hpf	NIL
CRYSTAL	NIL /hpf	NIL
CAST	NIL /hpf	NIL
BACTERIA	NIL	
MUCOUS THREAD	NIL	

Verified By:



10593

Lab Technologist

MOH License No:
Electronically signed at: 6/28/2025 10:18:00

Approved By:



DR ROSE MARY

Specialist Pathologist

MOH License No: 18178
Electronically signed at: 29/06/2025 12:57:00

Printed at: 30/06/2025 11:51:29 AM

Page: 3 of 3



NMC Healthcare LLC
CR No. 1858137
P.O. Box 295, Block 308
Building No. 012, Al Hadaresh
Subsidiary of NMC
T: +966 11 420 0222
F: +966 11 420 0288
www.nmc.com.sa



nmc specialty hospital, al-hail

P.O BOX : 613, Postal Code : 133
al-hail
24269222

Fitness Certificate

Empno: 6938

Date of issue : 29/06/2025

Ref No : 0000080/FIT/NMC/2025

This is to certify that Mr. / Mrs. *EJAZ AHMED* with file no *50102041* and Resident card no. *69827461* was *Examined* at *nmc specialty hospital, al-hail* on *29/06/2025* and will be *FIT TO WORK(MEDICALLY FIT)* from the medical point of view starting from *29/06/2025*

DIAGNOSIS

Remarks

TMT: NEGATIVE FOR ISCHEMIA

DR ERFAN GHODJANI

Place: *nmc specialty hospital, al-hail*

Signature

DR. ERFAN GHODJANI
Specialist Cardiology
MOH Lic. No: 23968
nmc specialty hospital, Al Ghabra





(Hospital Seal)

ELAZ ARKED
5/1/2011
Trace

Exam Start
Print Time
Date of Birth
Gender
Male

--- MPH
---%

RATE 115
BP ---/---



AHMED, EJAZ
50102041

Patient Information

6/29/2025 10:59:52 AM

Modified Bruce

ID: 50102041

Second ID:

Admission ID:

Date of Birth:

Age: 53 Years

Height: 167 cm

Weight: 113 kg

Gender: Male

Race: Unknown

Indications

Medications
Antihypertensive

Referring Physician: DR. ERFAN

Location: NMC HOSPITAL AL HAI

Procedure Type: TMT

Attending Phys: DR. ERFAN

Technician: AMEESH

Target HR: 142 bpm (85%)

Reasons for end: Target HR

Max HR (%MHR): 166 bpm (99%) Symptoms: NO CHEST PAIN

Diagnosis

Notes

Conclusions

The patient was tested using the Modified Bruce protocol for a duration of 07:59 min:ss and achieved 4.7 METs. A maximum heart rate of 166 bpm with a target predicted heart rate of 116% was obtained at 08:00. A maximum systolic blood pressure of 210/85 was obtained at 00:43 and a maximum diastolic blood pressure of 188/97 was obtained at 04:09. A maximum ST depression of -1.2 mm in aVR occurred at 08:41. A maximum ST elevation of +2.0 mm in V2 occurred at 08:50. The patient reacted target heart rate with appropriate heart rate and blood pressure response to exercise. No significant ST changes during exercise or recovery. No evidence of ischemia. Normal exercise stress test.

FREQUENT VPCs DURING EXERCISE, RECOMMENDATION: ECHOCARDIOGRAPHY, HYPERTENSION CONTROL.

Reviewed by:

UNCONFIRMED REPORT

Version: 6.2.5.50419

NMC SPECIALTY HOSPITAL AL HAI



AUDIOMETRY REPORT

Name of the Patient

Ejaz Ahmed

Sex

M

MRN

50102041

Date of Test

29/06/2025

U107.05

29-JUN-25 11:29


DP 4s

4 sec avg

SN: G11005649 G12014595

NAME:

Left: Pass



F2	L1	L2	DP	HF	SNR	P
2.0	65	54	2	-15	17	P
3.0	65	55	2	-11	7	P
4.0	60	52	2	-20	22	P
5.0	61	52	3	-38	22	P

U107.05

29-JUN-25 11:30

DP 4s

4 sec avg

SN: G11005649 G12014595

NAME:

Right: Pass



F2	L1	L2	DP	HF	SNR	P
2.0	65	55	2	-20	22	P
3.0	64	54	3	-12	15	P
4.0	63	54	4	-20	24	P
5.0	63	53	3	-20	23	P



NMCOMAN/DOC/NSG/75

Signature of the Technician

Name : EJAZ AHMED (80102041)

Policy No :

Customer : TRUCKOMAN EQUIPMENT RENTAL LLC (CORPORATE)

Certificate No :

Class : NORMAL (NORMAL)

Phone No : 95293385

ID Card

Insurance Card



Framingham Risk Score (2008)

Questions

- | | |
|--|-----------------|
| 1. Gender? | Male |
| 2. Age? | 50-54 |
| 3. Total Cholesterol? | <4.14 mmol/L |
| 4. HDL? | 0.9-1.16 mmol/L |
| 5. Systolic Blood Pressure? | ≥160 mmHg |
| 6. On Medication for Hypertension? | Yes |
| 7. Smoker? | No |
| 8. Diabetic? | Yes |
| 9. Known Vascular Disease (CAD, PVD, S...) | No |

About

The FRS estimates the 10 year risk of manifesting clinical CVD (CAD, Stroke, PVD, CHF, cardiac death). Although not examined in the 2008 model, it is common practice to double the FRS if there is a FHx of premature CAD in a 1st degree relative (men <55y, women <65y).

*The risk stratification tool for the ESC is the SCORE system which estimates 10y risk of CVD death. Patients with a 10y risk of CVD death ≥5% are considered high risk. The lipid guidelines recognize risk equivalents as a distinct category that warrant immediate treatment. For patients with an ESC SCORE ≥ 5% a 3 month trial of lifestyle measures is a reasonable starting point. If after 3 months the lipids remain above moderate risk targets and the SCORE remains ≥ 5% then intensive therapy to reach high risk targets is recommended.

Results

[Copy Results](#)

Estimated 10-year Global CVD Risk

29.4%*

Risk Category

High Risk*

Estimated Vascular Age

>80 Years*

*Due to this patient being diabetic, they are placed in the High Risk Category and should be treated based on the following guidelines.

Treatment Guidelines

ATP-III (2004)

Treatment Targets

LDL <100 mg/dL (<2.59 mmol/L)

Non-HDL <130 mg/dL (<3.37 mmol/L)

CCS (2009)

Treatment Targets

LDL <2 mmol/L (<77 mg/dL) or ≥50 % decrease in LDL-C

apoB <0.8 g/L (80 mg/dL)

ESC (2007, see info for more)

Treatment Targets

LDL <2.5 mmol/L (<80-100 mg/dL)

TChol <4.5 mmol/L (<155-175 mg/dL)

References

Created by  QxMD

Ralph B. D'Agostino, Sr., Ramachandran S. Vasan, Michael J. Pencina, Philip A. Wolf, Mark Cobain, Joseph M. Massaro and William B. Kannel.

General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Circulation 2008 February 12, 117 (6): 743-53

McPherson R et al.

Canadian Cardiovascular Society position statement—recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Canadian Journal of Cardiology 2006, 22 (11): 913-27

Management of Blood Cholesterol in Adults: Systematic Evidence Review from the Cholesterol Expert Panel.

Ian Graham et al.

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).

European Heart Journal, Volume 28, Issue 19, October 2007, Pages 2375-2414

The Framingham Risk Score (2008) calculator is created by QxMD.

Legal Notices and Disclaimer

© 2020 QxMD Software, Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER. [Click here for full notice and disclaimer.](#)

